02:03 PM EDT, 03/25/2024 (MT Newswires) -- Marvel Biosciences Corp. ( MBCOF ) and its subsidiary, Marvel Biotechnology Inc. on Monday reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, an expert on Tau pathology. Tau phosphorylation is a process where phosphates attach to a Tau protein in the brain.

The study demonstrated that short term oral dosing of MB-204 reduces Tau phosphorylation at key positions in Tau. According to the statement, abnormal Tau phosphorylation is a key feature of cognitive impairment and neurodegenerative diseases like Alzheimer's disease.

Using a mouse model of Tau hyperphosphorylation, pioneered by Dr. Planel, a 2.5 mg/kg oral dose of MB-204 "significantly" reduced Tau phosphorylation at multiple epitopes in the cortex of mice, including the AT8 site on Tau. "These are very promising preliminary results with MB-204," said Dr. Planel, "Considering that hyperphosphorylated Tau is present not only in Alzheimer's but also in other neurodegenerative diseases such as Parkinson's, Chronic Traumatic Encephalopathy, FTD, CBD, PSP etc., it has the potential to be effective for multiple pathologies."

Price: 0.18, Change: +0.01, Percent Change: +6.06